LymphedemaV1, Pmc, Checkpoint, bibRecord, 003936

Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation

Identifieur interne : 003936 ( Pmc/Checkpoint ); précédent : 003935; suivant : 003937

Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation

Auteurs : Daniel J. Tisch ; Moses J. Bockarie ; Zachary Dimber ; Benson Kiniboro ; Nandao Tarongka ; Fred E. Hazlett ; Will Kastens ; Michael P. Alpers ; James W. Kazura

Source :

The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2008.

RBID : PMC:2590750

Abstract

Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590750

PubMed: 18256431
PubMed Central: 2590750

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 002759
to stream Pmc, to step Curation: 002758

Links to Exploration step

PMC:2590750

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation</title>
<author><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J." last="Tisch">Daniel J. Tisch</name>
</author>
<author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name>
</author>
<author><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name>
</author>
<author><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name>
</author>
<author><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name>
</author>
<author><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E." last="Hazlett">Fred E. Hazlett</name>
</author>
<author><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name>
</author>
<author><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P." last="Alpers">Michael P. Alpers</name>
</author>
<author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">18256431</idno>
<idno type="pmc">2590750</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590750</idno>
<idno type="RBID">PMC:2590750</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">002759</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002759</idno>
<idno type="wicri:Area/Pmc/Curation">002758</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002758</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003936</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003936</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation</title>
<author><name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J." last="Tisch">Daniel J. Tisch</name>
</author>
<author><name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name>
</author>
<author><name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name>
</author>
<author><name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name>
</author>
<author><name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name>
</author>
<author><name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E." last="Hazlett">Fred E. Hazlett</name>
</author>
<author><name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name>
</author>
<author><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P." last="Alpers">Michael P. Alpers</name>
</author>
<author><name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="ISSN">0002-9637</idno>
<idno type="eISSN">1476-1645</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P2">Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in <italic>Wuchereria bancrofti</italic>
 microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <pmc-dir>properties manuscript</pmc-dir>
  <front><journal-meta><journal-id journal-id-type="nlm-journal-id">0370507</journal-id>
<journal-id journal-id-type="pubmed-jr-id">473</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Trop Med Hyg</journal-id>
<journal-title>The American journal of tropical medicine and hygiene</journal-title>
<issn pub-type="ppub">0002-9637</issn>
<issn pub-type="epub">1476-1645</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">18256431</article-id>
<article-id pub-id-type="pmc">2590750</article-id>
<article-id pub-id-type="manuscript">NIHMS77308</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Tisch</surname>
<given-names>Daniel J.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Bockarie</surname>
<given-names>Moses J.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Dimber</surname>
<given-names>Zachary</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Kiniboro</surname>
<given-names>Benson</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Tarongka</surname>
<given-names>Nandao</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Hazlett</surname>
<given-names>Fred E.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Kastens</surname>
<given-names>Will</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Alpers</surname>
<given-names>Michael P.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Kazura</surname>
<given-names>James W.</given-names>
</name>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="A1">Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio; Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea; Centre for International Health, Curtin University of Technology, Perth, Australia</aff>
</contrib-group>
<author-notes><corresp id="cor1"><label>*</label>
Address correspondence to James W. Kazura, Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH 44106-7286. E-mail <email>jxk14@po.cwru.edu</email>
</corresp>
<fn id="FN1"><p id="P1">Authors’ addresses: Daniel J. Tisch, Moses J. Bockarie, Fred E. Hazlett, Will Kastens, and James W. Kazura, Case Western Reserve University, Cleveland, OH. Zachary Dimber, Benson Kiniboro, and Nandao Tarongka, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea. Michael P. Alpers, Curtin University of Technology, Perth, Australia.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>3</day>
<month>11</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="ppub"><month>2</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>12</month>
<year>2008</year>
</pub-date>
<volume>78</volume>
<issue>2</issue>
<fpage>289</fpage>
<lpage>293</lpage>
<abstract><p id="P2">Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in <italic>Wuchereria bancrofti</italic>
 microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.</p>
</abstract>
<contract-num rid="AI1">U19 AI065717-01</contract-num>
<contract-sponsor id="AI1">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</contract-sponsor>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Alpers, Michael P" sort="Alpers, Michael P" uniqKey="Alpers M" first="Michael P." last="Alpers">Michael P. Alpers</name>
<name sortKey="Bockarie, Moses J" sort="Bockarie, Moses J" uniqKey="Bockarie M" first="Moses J." last="Bockarie">Moses J. Bockarie</name>
<name sortKey="Dimber, Zachary" sort="Dimber, Zachary" uniqKey="Dimber Z" first="Zachary" last="Dimber">Zachary Dimber</name>
<name sortKey="Hazlett, Fred E" sort="Hazlett, Fred E" uniqKey="Hazlett F" first="Fred E." last="Hazlett">Fred E. Hazlett</name>
<name sortKey="Kastens, Will" sort="Kastens, Will" uniqKey="Kastens W" first="Will" last="Kastens">Will Kastens</name>
<name sortKey="Kazura, James W" sort="Kazura, James W" uniqKey="Kazura J" first="James W." last="Kazura">James W. Kazura</name>
<name sortKey="Kiniboro, Benson" sort="Kiniboro, Benson" uniqKey="Kiniboro B" first="Benson" last="Kiniboro">Benson Kiniboro</name>
<name sortKey="Tarongka, Nandao" sort="Tarongka, Nandao" uniqKey="Tarongka N" first="Nandao" last="Tarongka">Nandao Tarongka</name>
<name sortKey="Tisch, Daniel J" sort="Tisch, Daniel J" uniqKey="Tisch D" first="Daniel J." last="Tisch">Daniel J. Tisch</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003936 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 003936 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:2590750
   |texte=   Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i   -Sk "pubmed:18256431" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation

Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in Papua New Guinea: Changes in Microfilaremia, Filarial Antigen, and Bm14 Antibody after Cessation

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki